ArticleCancer diagnosis & prognosis
Multicenter Retrospective Analysis of Pulmonary Sarcomatoid Carcinoma Clinically Diagnosed Using Small Biopsy Specimens.
Article in Cancer diagnosis & prognosis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aim: Pulmonary sarcomatoid carcinoma is a rare disease known for its aggressiveness, with numerous studies evaluating the efficacy of various therapeutic approaches. However, pulmonary sarcomatoid carcinoma is histologically defined according to WHO classification based on surgical specimens, whereas in clinical practice, most cases of advanced lung cancer are diagnosed based on small biopsy specimens. This retrospective study aimed to present the clinical course of patients diagnosed with pulmonary sarcomatoid carcinoma based on small biopsy specimens. Patients and Methods: Data of patients who were diagnosed with pulmonary sarcomatoid carcinoma based on small biopsy specimens and treated with platinum-doublet chemotherapy and/or an immune checkpoint inhibitor-containing regimen between 2005 and 2022 were analyzed. Results: Data from 12 patients were analyzed, including five patients treated with platinum-doublet chemotherapy and 11 patients treated with an immune checkpoint inhibitor-containing regimen. The median progression-free survival among the five patients treated with platinum-doublet chemotherapy was 1.5 months [95% confidence interval (CI)=0.7-4.1]. Of these, four patients subsequently received immune checkpoint inhibitor-containing therapy. The median overall survival from the initiation of platinum-doublet chemotherapy in these five patients was 14.7 months (95%CI=1.2-16.2). In contrast, 11 patients treated with immune checkpoint inhibitor therapy showed a median progression-free survival and overall survival of 8.9 months [95%CI=0.3-not estimated (NE)] and 10.8 months (95%CI=1.0-NE), respectively. Conclusion: Pulmonary sarcomatoid carcinoma diagnosed based on small biopsy specimens is refractory to platinum-doublet chemotherapy, and immune checkpoint inhibitor therapy may improve the prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.